SLEEPING SICKNESS
The DNDi & partners’ improved treatment for sleeping sickness NECT (Nifurtimox-Eflornithine Combination Therapy) has received the approval of the WHO to be placed on List of Essential Medicines (EML). More
ADVOCACY
DNDi and MSF call for scale-up of R&D for neglected diseases: greater governmental leadership is needed to foster medical innovation for neglected patients. More
VISCERAL LEISHMANIASIS
At the World Congress on Leishmaniasis held on Feb. 3-7 in India, DNDi organized two symposia on ongoing clinical studies and on early-stage R&D pipeline. More than 700 attendees from around the world gathered in this event. More
CHAGAS
100 years after the discovery of Chagas Disease, 100 million patients still infected. More about the 2009 Chagas Campaign More
MALARIA
DNDi and its partners are working to ensure access of ASAQ and ASMQ, two antimalarial fixed-dose combination therapies launched in 2007 and 2008. More
BIO 2009 DNDi held 2 symposia: one with iOWH on "Different Type of Partnerships which compose PDPs", the other on "Alternative IP management & tech transfer strategies"
June 23, 2009
Stakeholders’ & Africa Meeting DNDi Africa is hosting more than 150 Stakeholders to discuss Access Challenges, Strengthening Capacities & Favorable R&D Environment in Africa
June 22, 2009 Merck & Co., Inc. and Drugs for Neglected Diseases initiative Collaborate to Find Treatments for World's Most Neglected Tropical Diseases.
May 15, 2009 Eflornithine-Nifurtimox Combination Therapy (NECT) included onto Essential List of Medicines (EML) of WHO.
| SITEMAP | COPYRIGHT | DISCLAIMER | PRIVACY | @ 2009 DNDi All rights reserved |